Hidehito HORINOUCHI· @HHorinouchi · X·· 3 小时前评分70
正文 · 机器翻译
🔥第3期：Dalmelitinib + aumolertinib 对比化疗，用于 EGFR 突变、MET 扩增的 NSCLC（EGFR-TKI 治疗后）
🆙 @JCO_ASCO #ESMO26
🎯MET 主要终点
🎯IRC-PFS：6.2 vs 4.4个月（HR 0.601，p<0.001；n=314）
🎯ORR：59.6% vs 38.6%
🎯OS HR 0.840（数据尚不成熟，46.8%交叉）
🎯≥3级 TEAEs：50.0% vs 51.0%
☑️NCT06110663
🎙李子明医生与陆舜医生
#LCSM @OncoAlert @Larvol @EGFRResisters @metcrusaders
https://ascopubs.org/doi/10.1200/JCO-26-02432
12 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
dalmelitinib + aumolertinib
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org‼️ #ESMO26 simultaneous publication by Lu, et al. Dalmelitinib plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI-Resistance and MET-Amplification: A Randomized Phase 3 Trial Read full publication: https://bit.ly/4z9du0M在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com